Table 5 Key porphyrin biochemistry findings characteristic of active acute versus cutaneous presentation of AHPs
| Â | During acute attacks | Cutaneous manifestations | ||||||
|---|---|---|---|---|---|---|---|---|
Porphyria | Urine ALA/PBG | Total fecal porphyrins | FCR | Plasma scana (nm) | Urine ALA/PBG | Total fecal porphyrins | FCR | Plasma scana (nm) |
AIP | Highly increased > 4-fold URL | ±Normal | <1.5 | 615–620 | Not applicable | |||
HCP | Highly increased > 4-fold URL | Highly increased (Copro III) | >1.5 | 615–620 | ±Normal | Highly increased (Copro III) | >1.5 | 615–620 |
VP | Highly increased > 4-fold URL | Highly increased (Proto IX & Copro III) | >1.5 | 625–628 | ±Normal | Highly increased (Proto IX & Copro III) | >1.5 | 625–628 |
